ISA Pharma

ISA Pharma is a clinical-stage immunotherapy company based in the Netherlands, specializing in the development of synthetic long peptide (SLP) vaccines for cancer and infectious diseases. The company's proprietary SLP platform is designed to induce a robust and specific T-cell response by delivering optimal-length peptides that are processed and presented by dendritic cells. Its lead product candidate, ISA101b, targets HPV16-induced malignancies and is being evaluated in multiple Phase 2 trials in combination with anti-PD-1 checkpoint inhibitors. ISA Pharma also utilizes its AMPLIVANT technology, a potent TLR2 ligand adjuvant, to enhance the efficacy of its immunotherapies. The company maintains strategic partnerships with major industry players like Regeneron to advance its clinical pipeline.